SEHK:1093Pharmaceuticals
Does FDA-Backed Mpox mRNA Trial and AstraZeneca Tie-Up Recast the Bull Case For CSPC (SEHK:1093)?
CSPC Pharmaceutical Group recently reported three developments: U.S. FDA approval to begin clinical trials for its mpox mRNA vaccine, a US$10,000,000 milestone payment from AstraZeneca tied to their small-molecule collaboration, and a joint venture with AstraZeneca to build a biologics manufacturing facility in Shijiazhuang, China.
Together, these moves expand CSPC’s innovative vaccine and drug pipeline while pushing its manufacturing and quality systems further onto the global stage.
We’ll...